View ValuationThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsAtreca 将来の成長Future 基準チェック /06Atreca は収益が増加すると予測されています。EPS は、年間 増加すると予測されています25.8%。主要情報8.9%収益成長率25.75%EPS成長率Biotechs 収益成長23.2%収益成長率n/a将来の株主資本利益率n/aアナリストカバレッジLow最終更新日23 Feb 2024今後の成長に関する最新情報更新なしすべての更新を表示Recent updatesお知らせ • Jun 06Atreca, Inc. Announces Resignation of Franklin Berger from the BoardOn May 13, 2024, Mr. Franklin Berger resigned from the board of Atreca, Inc. Accordingly, Mr. Berger now serves on the boards of directors of three other public companies in addition to the Atea Board (Satellos Bioscience Inc., ESSA Pharma Inc., and Kezar Life Sciences, Inc.).お知らせ • May 21Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL) for $12.5 million on December 22, 2023. Pursuant to the agreement, Immunome will pay an aggregate purchase price of up to $12.5 million in cash, with $5.5 million due to the Atreca at the closing of the agreemeny and up to $7 million due upon the achievement of certain clinical-based milestone. The agreement have been unanimously approved by the board of directors of the Atreca. The agreement must also be approved by the Atreca’s stockholders, as a condition to the closing. In certain circumtances Atreca will pay a termination fee of $0.5 million to Immunome. Transaction is expected to close in the second quarter of 2024. John T. McKenna and Matthew Silverman of Cooley LLP acted as legal advisor to Atreca. Kingsley Taft and Steven Green of Goodwin Procter LLP acted as legal advisor to Immunome.Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL) on May 20, 2024.お知らせ • Apr 02Atreca, Inc. Files Form 15Atreca, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Class A Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Class A Common Stock was $0.0001 per share.お知らせ • Mar 21Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI IndexAtreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Indexお知らせ • Mar 19Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite IndexAtreca, Inc. has been dropped from NASDAQ Composite Index .お知らせ • Mar 12Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid RequirementAs previously reported, on September 8, 2023, Atreca, Inc. (the Company") received written notification (the Initial Notice") from The Nasdaq Stock Market LLC (Nasdaq") notifying it that on September 7, 2023, the average closing price of the Company's Class A common stock, $0.0001 par value per share (the Class A Common Stock"), over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had 180 calendar days from the date of the Initial Notice, or March 6, 2024, to regain compliance with the Minimum Bid Requirement (the Grace Period"), subject to a potential 180-day extension. To regain compliance, the closing bid price of the Class A Common Stock must have been at least $1.00 per share for a minimum of ten consecutive business days within the Grace Period. On March 8, 2024, the Company received written notification from Nasdaq indicating that it had failed to achieve compliance with the Minimum Bid Requirement prior to the expiration of the Grace Period, and therefore the Class A Common Stock will be delisted from trading on Nasdaq. The Company does not intend to request an extension of the Grace Period or any administrative hearing to delay such delisting. As a result, the Class A Common Stock will be suspended from trading at the opening of business on March 19, 2024. Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission (the SEC") to remove the Class A Common Stock from listing and registration, though Nasdaq has not specified the date on which the Form 25-NSE will be filed. If Nasdaq has not filed the Form 25-NSE by March 20, 2024, the Company intends to file a Form 25 with the SEC on such date to remove the Class A Common Stock from listing and registration on Nasdaq. The Company plans to file a Form 15with the SEC to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended, shortly thereafter. The Company expects that its Class A Common Stock will be eligible to be quoted over-the-counter," however, no assurance can be given that quotation of the Class A Common Stock will be commenced or maintained on an over-the-counter market or any other quotation medium.New Risk • Feb 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$65m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$65m free cash flow). Shares are highly illiquid. Revenue is less than US$1m. Market cap is less than US$10m (€8.54m market cap, or US$9.19m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$51m net loss in 3 years).Board Change • Jan 12Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Independent Director Stacey Ma was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Board Change • Nov 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Independent Director Stacey Ma was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.業績と収益の成長予測MUN:0C1 - アナリストの将来予測と過去の財務データ ( )USD Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数12/31/2026N/A-52N/AN/A112/31/2025N/A-48N/AN/A212/31/2024N/A-43N/AN/A212/31/2023N/A-80N/AN/A29/30/2023N/A-98-65-65N/A6/30/2023N/A-85-65-64N/A3/31/2023N/A-93-71-70N/A12/31/2022N/A-97-82-81N/A9/30/2022N/A-105-86-81N/A6/30/2022N/A-110-88-81N/A3/31/2022N/A-108-93-69N/A12/31/2021N/A-109-96-61N/A9/30/2021N/A-103-96-63N/A6/30/2021N/A-98-93-62N/A3/31/2021N/A-92-82-66N/A12/31/2020N/A-86-72-67N/A9/30/2020N/A-83-70-65N/A6/30/2020N/A-76-71-65N/A3/31/2020N/A-74-67-63N/A12/31/2019N/A-67-62-59N/A9/30/2019N/A-59-56-53N/A6/30/2019N/A-53-47-45N/A3/31/2019N/A-44-41-40N/A12/31/2018N/A-38-36-35N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: 0C1今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 0C1今後 3 年間、利益が出ない状態が続くと予測されています。高成長収益: 0C1今後 3 年間、利益が出ない状態が続くと予測されています。収益対市場: 0C1の収益がGerman市場よりも速く成長すると予測されるかどうかを判断するにはデータが不十分です。高い収益成長: 0C1来年は収益がないと予測されています。一株当たり利益成長率予想将来の株主資本利益率将来のROE: 0C1の 自己資本利益率 が 3 年後に高くなると予測されるかどうかを判断するにはデータが不十分です成長企業の発掘7D1Y7D1Y7D1YPharmaceuticals-biotech 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2024/04/17 06:35終値2024/01/19 00:00収益2023/09/30年間収益2022/12/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Atreca, Inc. 2 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。11 アナリスト機関Michael UlzBairdKumaraguru RajaBrookline Capital MarketsJohn NewmanCanaccord Genuity8 その他のアナリストを表示
お知らせ • Jun 06Atreca, Inc. Announces Resignation of Franklin Berger from the BoardOn May 13, 2024, Mr. Franklin Berger resigned from the board of Atreca, Inc. Accordingly, Mr. Berger now serves on the boards of directors of three other public companies in addition to the Atea Board (Satellos Bioscience Inc., ESSA Pharma Inc., and Kezar Life Sciences, Inc.).
お知らせ • May 21Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL).Immunome, Inc. (NasdaqCM:IMNM) entered into an agreement to acquire Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL) for $12.5 million on December 22, 2023. Pursuant to the agreement, Immunome will pay an aggregate purchase price of up to $12.5 million in cash, with $5.5 million due to the Atreca at the closing of the agreemeny and up to $7 million due upon the achievement of certain clinical-based milestone. The agreement have been unanimously approved by the board of directors of the Atreca. The agreement must also be approved by the Atreca’s stockholders, as a condition to the closing. In certain circumtances Atreca will pay a termination fee of $0.5 million to Immunome. Transaction is expected to close in the second quarter of 2024. John T. McKenna and Matthew Silverman of Cooley LLP acted as legal advisor to Atreca. Kingsley Taft and Steven Green of Goodwin Procter LLP acted as legal advisor to Immunome.Immunome, Inc. (NasdaqCM:IMNM) completed the acquisition of Substantially all Assets of Atreca, Inc. (NasdaqGS:BCEL) on May 20, 2024.
お知らせ • Apr 02Atreca, Inc. Files Form 15Atreca, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Class A Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Class A Common Stock was $0.0001 per share.
お知らせ • Mar 21Atreca, Inc.(OTCPK:BCEL) dropped from S&P TMI IndexAtreca, Inc.(OTCPK:BCEL) dropped from S&P TMI Index
お知らせ • Mar 19Atreca, Inc.(OTCPK:BCEL) dropped from NASDAQ Composite IndexAtreca, Inc. has been dropped from NASDAQ Composite Index .
お知らせ • Mar 12Atreca, Inc. Receives Written Notification from Nasdaq Regarding Minimum Bid RequirementAs previously reported, on September 8, 2023, Atreca, Inc. (the Company") received written notification (the Initial Notice") from The Nasdaq Stock Market LLC (Nasdaq") notifying it that on September 7, 2023, the average closing price of the Company's Class A common stock, $0.0001 par value per share (the Class A Common Stock"), over the prior 30 consecutive trading days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on Nasdaq under Nasdaq Listing Rule 5450(a)(1) (the Minimum Bid Requirement"). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company had 180 calendar days from the date of the Initial Notice, or March 6, 2024, to regain compliance with the Minimum Bid Requirement (the Grace Period"), subject to a potential 180-day extension. To regain compliance, the closing bid price of the Class A Common Stock must have been at least $1.00 per share for a minimum of ten consecutive business days within the Grace Period. On March 8, 2024, the Company received written notification from Nasdaq indicating that it had failed to achieve compliance with the Minimum Bid Requirement prior to the expiration of the Grace Period, and therefore the Class A Common Stock will be delisted from trading on Nasdaq. The Company does not intend to request an extension of the Grace Period or any administrative hearing to delay such delisting. As a result, the Class A Common Stock will be suspended from trading at the opening of business on March 19, 2024. Nasdaq will file a Form 25-NSE with the Securities and Exchange Commission (the SEC") to remove the Class A Common Stock from listing and registration, though Nasdaq has not specified the date on which the Form 25-NSE will be filed. If Nasdaq has not filed the Form 25-NSE by March 20, 2024, the Company intends to file a Form 25 with the SEC on such date to remove the Class A Common Stock from listing and registration on Nasdaq. The Company plans to file a Form 15with the SEC to suspend its reporting obligations under the Securities Exchange Act of 1934, as amended, shortly thereafter. The Company expects that its Class A Common Stock will be eligible to be quoted over-the-counter," however, no assurance can be given that quotation of the Class A Common Stock will be commenced or maintained on an over-the-counter market or any other quotation medium.
New Risk • Feb 13New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -US$65m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-US$65m free cash flow). Shares are highly illiquid. Revenue is less than US$1m. Market cap is less than US$10m (€8.54m market cap, or US$9.19m). Minor Risk Currently unprofitable and not forecast to become profitable over next 3 years (US$51m net loss in 3 years).
Board Change • Jan 12Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Independent Director Stacey Ma was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Board Change • Nov 30Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 7 experienced directors. 4 highly experienced directors. Independent Director Stacey Ma was the last director to join the board, commencing their role in 2021. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.